+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

From
From
US Axial Spondyloarthritis Market outlook to 2028 - Product Thumbnail Image

US Axial Spondyloarthritis Market outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
US HUMIRA Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

US HUMIRA Market Size, Forecast, and Market Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • United States
From
From
Biosimilar Monoclonal Antibodies Market Report 2022-2032 - Product Thumbnail Image

Biosimilar Monoclonal Antibodies Market Report 2022-2032

  • Report
  • July 2022
  • 461 Pages
  • Global
From
From
From
From
From
From
From
From
OLUMIANT Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

OLUMIANT Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more